# BullFrog AI Holdings, Inc.: overview BFRG · Nasdaq · CIK 1829247 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bfrg.md) · [Financials](/companies/bfrg/financials.md) · [Filings](/companies/bfrg/filings.md) · [Insiders](/companies/bfrg/insiders.md) Latest reported revenue: [$215.4k](/filings/0001628280-26-057121.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-057121). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | [33.3](/filings/0001628280-26-057121.md) | [83.4](/filings/0001493152-25-023496.md) | [0.0 d](/filings/0001493152-26-011644.md) | not reported | [215](/filings/0001628280-26-057121.md) | | Gross margin | % | not reported | not reported | not reported | [19.6%](/filings/0001628280-26-057121.md) | [18.4%](/filings/0001493152-25-023496.md) | not reported | not reported | [49.6%](/filings/0001628280-26-057121.md) | | Operating margin | % | not reported | not reported | not reported | [(4419.1%)](/filings/0001628280-26-057121.md) | [(1881.8%)](/filings/0001493152-25-023496.md) | not reported | not reported | [(658.8%)](/filings/0001628280-26-057121.md) | | Net margin | % | not reported | not reported | not reported | [(4356.2%)](/filings/0001628280-26-057121.md) | [(1860.2%)](/filings/0001493152-25-023496.md) | not reported | not reported | [(636.8%)](/filings/0001628280-26-057121.md) | | Diluted EPS | $ per share | [(0.22)](/filings/0001493152-25-023496.md) | not reported | [(0.21)](/filings/0001493152-26-023068.md) | [(0.15)](/filings/0001628280-26-057121.md) | [(0.15)](/filings/0001493152-25-023496.md) | not reported | [(0.12)](/filings/0001493152-26-023068.md) | [(0.07)](/filings/0001628280-26-057121.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [10.0](/filings/0001493152-24-011964.md) | [65.0](/filings/0001493152-25-010367.md) | not reported | [117](/filings/0001493152-26-011644.md) | | Gross margin | % | not reported | [92.0%](/filings/0001493152-24-011964.md) | [92.0%](/filings/0001493152-25-010367.md) | not reported | [18.8%](/filings/0001493152-26-011644.md) | | Operating margin | % | not reported | [(24558.0%)](/filings/0001493152-24-011964.md) | [(8257.7%)](/filings/0001493152-25-010367.md) | not reported | [(5652.4%)](/filings/0001493152-26-011644.md) | | Net margin | % | not reported | [(28024.9%)](/filings/0001493152-24-011964.md) | [(8239.8%)](/filings/0001493152-25-010367.md) | not reported | [(5569.6%)](/filings/0001493152-26-011644.md) | | Diluted EPS | $ per share | not reported | [(0.70)](/filings/0001493152-24-011964.md) | [(0.89)](/filings/0001493152-25-010367.md) | [(0.85)](/filings/0001493152-26-011644.md) | [(0.63)](/filings/0001493152-26-011644.md) | | Free cash flow | $k | not reported | [(920)](/filings/0001493152-24-011964.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bfrg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $256.7k | 361,546 | | New +361,546 | | [J. Safra Sarasin Holding AG](/funds/1890222.md) | 2026-06-30 | $191.1k | 113,720 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $75.6k | 106,484 | | Added +80,913 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $74.5k | 104,928 | | Added +25,068 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $65.0k | 91,596 | | Added +25,022 | | [Anson Funds Management LP](/funds/1491072.md) | 2026-06-30 | $57.3k | 80,750 | | Unchanged | | [Vontobel Holding Ltd.](/funds/1588340.md) | 2026-06-30 | $49.7k | 70,000 | | Added +32,000 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $46.8k | 65,980 | | New +65,980 | | [ACT Advisors, LLC.](/funds/1842554.md) | 2026-06-30 | $40.0k | 56,351 | | New +56,351 | | [FORTEM FINANCIAL GROUP, LLC](/funds/1766509.md) | 2026-06-30 | $35.5k | 50,000 | | Unchanged | ## Recent filings [All 205 filings](/companies/bfrg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-20 | 09:00 ET | [8-K](/filings/0001628280-26-058143.md) | 3.01 Delisting notice | 0001628280-26-058143 | | 2026-08-14 | 16:13 ET | [10-Q](/filings/0001628280-26-057121.md) | Quarterly report, period 2026-06-30 | 0001628280-26-057121 | | 2026-06-15 | 17:30 ET | [8-K](/filings/0001493152-26-028747.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-028747 | | 2026-05-29 | 16:34 ET | [S-1](/filings/0001493152-26-026390.md) | Registration statement | 0001493152-26-026390 | | 2026-05-14 | 16:05 ET | [10-Q](/filings/0001493152-26-023068.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023068 | | 2026-04-30 | 16:15 ET | [DEF 14A](/filings/0001493152-26-020511.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020511 | | 2026-04-22 | 09:00 ET | [8-K](/filings/0001493152-26-018458.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018458 | | 2026-04-21 | 17:21 ET | [8-K](/filings/0001493152-26-018365.md) | 5.08 Item not in the standard list; 9.01 Financial statements and exhibits | 0001493152-26-018365 | | 2026-04-13 | 16:38 ET | [8-K](/filings/0001493152-26-016378.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-016378 | | 2026-04-01 | 14:56 ET | [8-K](/filings/0001493152-26-014595.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-014595 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011644.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/67236e30-01c4-498e-a28b-1d3c29e3c700) ## About the filer - CIK: 1829247 - Tickers: BFRG, BFRGW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.